CSPAN U.S. House Of Representatives August 17, 1116
Improvement over existing therapies. This is based on the successful breakthrough designation created by congress back in 20 is 12. This has worked and accelerated oncology drug reviews by more than two years. In short h. R. 4374 addresses the access to the newest available products by expanding the circumstances under which emergency use authorizations can be issued and by establishing a pathway to full approval of products at the secretary of defense requests. Policies were bipartisan and developed with input from the administration and authorizing committees in the house and the senate. C. ...